By CapitalSnitch Research Desk · updated Oct 11, 2026 · data from SEC filings and official Congress disclosures
Over the last 12 months, two Lipocine Inc. the people running the company picked up shares on the open market, about $517,000 in total, and none of them sold.
Higuchi John W. (Director) made the biggest buy, worth around $252,000. Notably, at least one C-suite executive was among the buyers.
Zooming out by quarter: 2 quarters in a row of net buying by insiders. Insiders bought in 2 of the last 7 full quarters. Big money check: 36 institutions held LPCN as of Q2 2026, and funds were split between buying and selling.
Are insiders buying or selling LPCN stock?
In the last 12 months Lipocine Inc. insiders made open-market purchases worth about $517,000 and sales worth about $0. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
When was the last insider trade in LPCN?
The most recent open-market insider trade in LPCN was filed on 2026-10-01.
How many institutions own LPCN?
36 investment managers reported holding LPCN in SEC Form 13F filings for Q2 2026.
Has any member of Congress traded LPCN?
No congressional trades in LPCN were reported in the past two years. The full list is free on CapitalSnitch.
Free weekly email: the week's biggest insider buys and Congress trades, every Monday. No spam, one-click unsubscribe.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1).
Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).